In ₹ Crore except Per Share Latest Annual | AMRUTANJAN FY26 | FERMENTA no data | JAGSNPHARM FY26 | NGLFINE FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | ◆ 24.63× | — | 36.54× | 34.67× | 35.61× -31% | |
| P/B | ◆ 3.85× | — | 5.67× | 5.07× | 5.37× -28% | |
| EV/EBITDA | ◆ 18.66× | — | 26.79× | 23.87× | 25.33× -26% | |
| Market Cap | ₹1,426 Cr | — | ₹1,566 Cr | ₹1,669 Cr | ₹1,617 Cr -12% | |
| Growth | ||||||
| Revenue CAGR 3Y | 9.80% | — | 6.66% | ◆ 21.68% | 14.17% -31% | |
| Revenue CAGR 5Y | ◆ 13.96% | — | 8.85% | — | 8.85% +58% | |
| Net Income CAGR 3Y | 13.29% | — | 17.26% | ◆ 32.91% | 25.09% -47% | |
| Revenue YoY (latest Q) | 9.49% | — | 8.76% | ◆ 33.57% | 21.16% -55% | |
| Net Income YoY (latest Q) | -47.47% | — | 22.18% | ◆ 99.09% | 60.64% -178% | |
| Profitability | ||||||
| EBITDA Margin | 15.06% | — | ◆ 20.22% | 14.51% | 17.36% -13% | |
| Net Income Margin | 11.52% | — | ◆ 15.00% | 9.61% | 12.30% -6% | |
| Return on Common Equity | ◆ 15.64% | — | 15.60% | 14.62% | 15.11% +4% | |
| Return on Capital Employed | ◆ 18.13% | — | 16.86% | 13.43% | 15.14% +20% | |
| Return on Assets | 11.38% | — | ◆ 13.60% | 8.82% | 11.21% +2% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.00× | — | 0.00× | 0.33× | 0.17× -100% | |
| Interest Coverage | ◆ 355.72× | — | 47.31× | 11.89× | 29.60× +1102% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹503 Cr | — | ₹287 Cr | ₹501 Cr | ₹394 Cr +28% | |
| Net Income | ₹57.9 Cr | — | ₹43.1 Cr | ₹48.1 Cr | ₹45.6 Cr +27% | |
| Total Assets | ₹509 Cr | — | ₹317 Cr | ₹545 Cr | ₹431 Cr +18% | |
| EPS | ₹20.03 | — | ₹6.4 | ₹77.9 | ₹42.15 -52% | |
| Book Value per Share | ₹128.06 | — | ₹41.24 | ₹532.91 | ₹287.08 -55% | |